Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023. The in-person poster presentation reveals a synthetic lethal relationship between ecDNA bearing tumors and checkpoint kinase 1 (CHK1) inhibition, providing a potential therapeutic strategy for addressing ecDNA-enabled oncogene amplified cancers.

Presentation details:

Poster Title: Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Antitumor Agents 3

Abstract Presentation Number: 1626

Date and Time: April 17, 2023, 9:00 a.m. - 12:30 p.m. ET

Location: Section 17

About ecDNA

Extrachromosomal DNA (“ecDNA”) are circular units of nuclear DNA that are physically distinct from chromosomes and are found within cancer cells. ecDNA encode full length genes, including oncogenes and regulatory regions, are highly transcriptionally active, and lack centromeres. ecDNA replicate and express within cancer cells and, due to their lack of centromeres, can be asymmetrically passed to daughter cells during cell division, leading to focal gene amplification and copy number heterogeneity in cancer. By leveraging the plasticity afforded by ecDNA, cancer cells have the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including targeted therapy, immunotherapy, chemotherapy, or radiation, thereby making ecDNA one of cancer cells’ primary mechanisms of growth, recurrence, and treatment resistance. ecDNA are not found in healthy cells but are present in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.

About Boundless Bio

Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005006/en/